Answers are grounded in this paper and cite their sources.
OBJECTIVES: The phase 1 SELECT-YOUTH trial demonstrated efficacy and safety of upadacitinib for pcJIA in pediatric patients. This second interim analysis incorporates the results from an additional cohort providing efficacy results up to 48 weeks and cumulative safety up to 156 weeks. METHODS: 122 patients with pcJIA, aged 2 to < 18 years received upadacitinib, dosed either twice-daily oral solution or once-daily extended-release tablet, based on body weight. Analyses included patients who received at least one dose. Efficacy and safety outcomes were evaluated through week 156 using as observed and non-responder imputation methods. Efficacy was reported up to 48 weeks; safety was assessed at all study time points. Efficacy included JIA-ACR 30/50/70/90/100 response rates, Juvenile Arthritis Disease Activity Score (JADAS)-27, C-HAQ, and pain. RESULTS: At 48 weeks, JIA-ACR response rates were: 96.3% (JIA-ACR30), 93.6% (JIA-ACR50), 89.0% (JIA-ACR70), 72.5% (JIA-ACR90), 57.8% (JIA-ACR100). Low disease activity (JADAS-27 [CRP] ≤ 3.8) was achieved by 79.4%, with 49.5% reaching inactive disease status (JADAS-27 [CRP] ≤ 1). C-HAQ change from baseline to week 48 was -0.64 (n = 108) and rapid improvement in pain was evident by week 12 and persisted throughout 48 weeks. Treatment-emergent adverse events were generally mild to moderate, occurring at 499.6 events per 100 patient-years (E/100 PY; n = 122). Most frequent events (per 100 PY) of special interest were hepatic disorders (7.5), bone fractures (4.3), and CPK elevation (3.5). No deaths occurred. CONCLUSIONS: In the SELECT-YOUTH trial, bodyweight-based dosing of upadacitinib maintained efficacy in pediatric patients with pcJIA, and its safety profile was consistent with established safety profile. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03725007; EUDRACT: 2018-000715-25.
No takes yet. Share an insight, caveat, or question.
Brunner et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: